Denali Therapeutics Inc.

Equities

DNLI

US24823R1059

Market Closed - Nasdaq Other stock markets 04:00:00 2026-06-05 pm EDT			5-day change	1st Jan Change
19.52 ^USD	-3.08%		-7.22%	+18.23%

Jun. 05	Denali Therapeutics Inc. Presents at Jefferies Global Healthcare Conference 2026, Jun-04-2026 08:45 AM
May. 26	Denali Therapeutics' Focus Shifts to Other Pipeline Assets After Phase 2b Study Failure, Morgan Stanley Says	MT

Transcript : Denali Therapeutics Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-10-2025 01

Published on 06/10/2025 at 02:20 pm EDT - Modified on 06/10/2025 at 07:00 pm EDT

S&P Capital IQ

Presenter Speech
Salveen Richter (Analysts)

Great. Good afternoon, everyone. Thank you so much for joining us. I'm Salveen Richter, biotechnology analyst at Goldman Sachs. I'm really pleased to be

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Denali Therapeutics Inc.

Jun. 05	Denali Therapeutics Inc. Presents at Jefferies Global Healthcare Conference 2026, Jun-04-2026 08:45 AM
May. 26	Denali Therapeutics' Focus Shifts to Other Pipeline Assets After Phase 2b Study Failure, Morgan Stanley Says	MT
May. 22	Morgan Stanley Cuts Price Target on Denali Therapeutics to $35 From $40, Keeps Overweight Rating	MT
May. 22	Wall Street Packs for the Long Weekend
May. 22	Wedbush Cuts Price Target on Denali Therapeutics to $20 From $23, Keeps Outperform Rating	MT
May. 22	Deutsche Bank Adjusts Denali Therapeutics Price Target to $31 From $35, Maintains Buy Rating	MT
May. 22	Denali, Biogen Discontinue Parkinson's Drug Development Amid Phase 2 Setback; Shares Down Pre-Bell	MT
May. 21	Biogen, Denali scrap Parkinson's drug after failure in mid-to-late stage study	RE
May. 21	Biogen Inc. and Denali Therapeutics Inc. Provide Update on Phase 2b LUMA Study Of BIIB122 In Early-Stage Parkinson?s Disease	CI
May. 14	Morgan Stanley Trims Price Target on Denali Therapeutics to $40 From $42, Keeps Overweight Rating	MT
May. 12	Denali Therapeutics Inc. Presents at Bank of America Global Healthcare Conference 2026, May-12-2026 03:00 PM
May. 11	Denali Therapeutics Seeing Encouraging Signals From Avlayah Launch, Oppenheimer Says	MT
May. 08	Wedbush Adjusts Denali Therapeutics Price Target to $23 From $25, Maintains Outperform Rating	MT
May. 07	Denali Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
Apr. 21	Wedbush Cuts Price Target on Denali Therapeutics to $25 From $30, Keeps Outperform Rating	MT